ABX544, a programme targeting the development of a treatment for EBOLA virus infection
Building on its experience in developing specific polyclonal antibodies, ABIVAX has initiated a programme targeting the development of a treatment for EBOLA virus infection. The chosen strategy permits the rapid production and purification of neutralising antibodies from immunised animals. These antibodies will be directed to targets conserved between the different strains circulating in human populations, permitting a large degree of protection and limiting the risk of therapeutic failure when faced with new variants of the virus. The potential for the therapeutic efficacy of this approach, the flexibility of production in urgent conditions, as well as the possibility of transport and storage in hot countries will be of great advantage in epidemic situations. ABIVAX aims to start a phase I study in 2017 to demonstrate safety of the product before commencing clinical studies in epidemic areas. These antibodies could be used to treat poeple infected with Ebola virus as well as the prevention of infection of persons in contact with cases.